Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein

• Published in: Biochemical pharmacology 2005-08, Vol.70 (4), p.627-639
• Main Authors: Zhang, Shuzhong, Yang, Xinning, Coburn, Robert A., Morris, Marilyn E.
• Format: Article
• Language: English
• Subjects: Algorithms; ATP Binding Cassette Transporter, Sub-Family G, Member 2; ATP-Binding Cassette Transporters - antagonists & inhibitors; Biological and medical sciences; Breast cancer resistance protein; Cell Line, Tumor; Flavonoids; Flavonoids - pharmacology; Humans; Medical sciences; Membrane transport; Mitoxantrone transport; Neoplasm Proteins - antagonists & inhibitors; Pharmacology. Drug treatments; Quantitative structure activity relationships; Structure activity relationships; Structure-Activity Relationship
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2005.05.017

Breast cancer resistance protein (BCRP) is a newly identified ABC transporter, which plays an important role in drug disposition and represents an additional mechanism for the development of MDR. Flavonoids, a major class of natural compounds widely present in foods and herbal products, have been shown to be BCRP inhibitors. The objective of the present study was to elucidate the SAR and derive a QSAR model for flavonoid–BCRP interaction. The EC 50 values for increasing mitoxantrone accumulation in MCF-7 MX100 cells for 25 flavonoids, from five flavonoid subclasses, were determined in this study or obtained from our previous publication [Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(7):1263–73], and ranged from 0.07 ± 0.02 μM to 183 ± 21.7 μM. We found that the presence of a 2,3-double bond in ring C, ring B attached at position 2, hydroxylation at position 5, lack of hydroxylation at position 3 and hydrophobic substitution at positions 6, 7, 8 or 4′, are important structural properties important for potent flavonoid–BCRP interaction. These structural requirements are similar but not identical to those for potent flavonoid–NBD2 (P-glycoprotein) interaction, indicating that inhibition of BCRP by flavonoids may involve, in part, the binding of flavonoids with the NBD of BCRP. In addition, a QSAR model consisting three structural descriptors was constructed, and both internally and externally validated, suggesting the model could be used to quantitatively predict BCRP inhibition activity of flavonoids. These findings should be useful for predicting BCRP inhibition activity of other untested flavonoids and for guiding the synthesis of potent BCRP inhibitors for potential clinical application.